High-dose IV ascorbic acid therapy in CCUS patients with TET2 mutations

This was a phase II trial, evaluating the safety/efficacy of high-dose IV-ascorbic acid in patients with TET2 mutant CCUS. Eight of 10 patients enrolled were eligible for response assessment. At week 20, there were no responses by IWG MDS criteria. NCT03418038

Saved in:
Bibliographic Details
Published in:Blood 2024-10
Main Authors: Xie, Zhuoer, Fernandez, Jenna, Lasho, Terra L, Finke, Christy M., Amundson, Michelle, McCullough, Kristen, LaPlant, Betsy, Mangaonkar, Abhishek A, Gangat, Naseema, Reichard, Kaaren K, Elliott, Michelle Ann, Witzig, Thomas E., Patnaik, Mrinal M.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This was a phase II trial, evaluating the safety/efficacy of high-dose IV-ascorbic acid in patients with TET2 mutant CCUS. Eight of 10 patients enrolled were eligible for response assessment. At week 20, there were no responses by IWG MDS criteria. NCT03418038
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.2024024962